Prime Medicine reported a net margin of -3,648.96% for the quarter ended Jun 2026. These financial ratios cover 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||
| EBT Margin | -7,720.30% | -25,128.23% | -1,936.60% | -3,568.78% | -4,716.68% | -4,312.82% | -5,671.24% | -5,798.25% | -3,682.58% | ||||||
| EBIT Margin | -8,179.53% | -25,948.33% | -2,025.74% | -3,603.30% | -4,787.17% | -4,405.96% | -5,800.48% | -5,917.52% | -3,750.87% | ||||||
| EBITDA Margin | -8,179.53% | -25,948.33% | -2,025.74% | -3,603.30% | -4,787.17% | -4,405.96% | -5,800.48% | -5,917.52% | -3,750.87% | ||||||
| Operating Margin | -8,179.53% | -25,948.33% | -2,025.74% | -3,603.30% | -4,787.17% | -4,405.96% | -5,800.48% | -5,917.52% | -3,750.87% | ||||||
| Net Margin | -7,742.98% | -25,128.23% | -1,936.60% | -3,568.78% | -4,716.68% | -4,129.14% | -5,498.69% | -5,738.55% | -3,648.96% | ||||||
| FCF Margin | -11,849.58% | -13,009.09% | 662.12% | -3,526.75% | -3,855.07% | -2,880.49% | -4,480.43% | -5,014.49% | -3,560.83% | ||||||
| Efficiency | |||||||||||||||
| Assets AverageAssets Avg. | 287.79M | 338.63M | 298.91M | 260.00M | 216.50M | 252.62M | 285.54M | 296.24M | 315.15M | 312.84M | 303.59M | 332.01M | 363.87M | 318.73M | 271.88M |
| Asset Utilization RatioAsset Util. | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |||||
| Valuation | |||||||||||||||
| Price to EarningsP/E | -15.51 | -30.36 | -33.62 | -18.31 | -13.14 | -18.36 | -11.15 | -9.67 | -9.06 | -5.03 | -6.32 | -19.75 | -11.20 | -12.80 | -15.84 |
| Price to SalesP/S | 0.00M | 0.00M | 175.44 | 179.51 | 297.94 | 815.44 | 615.98 | 734.28 | 577.92 | ||||||
| Price to BookP/B | 1.99 | 4.29 | 5.93 | 4.79 | 6.48 | 3.45 | 3.14 | 2.68 | 2.50 | 2.44 | 5.46 | 6.17 | 4.27 | 8.19 | 16.75 |
| Enterprise Value | 343.61M | 952.52M | 1,223.78M | 767.97M | 746.55M | 636.04M | 458.78M | 336.97M | 195.55M | 120.67M | 233.86M | 790.49M | 338.51M | 493.04M | 571.85M |
| EV to EBIT | -8.88 | -23.79 | -27.04 | -14.92 | -10.97 | -13.16 | -8.24 | -6.21 | -4.42 | -2.30 | -4.38 | -14.65 | -6.96 | -9.73 | -13.21 |
| EV to EBITDA | -8.88 | -23.79 | -27.04 | -14.92 | -10.97 | -13.16 | -8.24 | -6.21 | -4.42 | -2.30 | -4.38 | -14.65 | -6.96 | -9.73 | -13.21 |
| Market Capitalization | 629.70M | 1,195.90M | 1,425.00M | 928.47M | 862.76M | 840.15M | 616.96M | 507.59M | 382.99M | 261.01M | 332.20M | 998.91M | 516.19M | 628.54M | 666.92M |
| Price to FCFP/FCF | -17.72 | -27.08 | -33.77 | -22.07 | -18.88 | -12.00 | -13.02 | -18.67 | 26.50 | -5.09 | -7.73 | -28.31 | -13.75 | -14.64 | -16.23 |
| EV to FCF | -9.67 | -21.57 | -29.00 | -18.25 | -16.33 | -9.08 | -9.68 | -12.39 | 13.53 | -2.35 | -5.44 | -22.40 | -9.02 | -11.49 | -13.92 |
| EV to CFO | -11.19 | -22.92 | -29.98 | -19.61 | -17.02 | -9.39 | -10.09 | -13.00 | 12.04 | -2.47 | -5.65 | -22.56 | -9.09 | -11.54 | -13.93 |
| Return Ratios | |||||||||||||||
| Return on Sales [ROS]ROS | -8,179.53% | -37,819.80% | -25,948.33% | -2,025.74% | -3,603.30% | -4,787.17% | -4,405.96% | -5,800.48% | -5,917.52% | -3,750.87% | |||||
| Return on Capital Employed [ROCE]ROCE | -44.64% | -43.42% | -57.60% | -79.51% | -127.94% | -93.39% | -84.41% | -87.58% | -73.04% | -74.14% | -75.78% | -68.68% | -63.83% | -73.15% | -81.82% |
| Return on Assets [ROA]ROA | -42.33% | -40.57% | -50.32% | -66.07% | -91.52% | -80.95% | -76.15% | -74.01% | -62.16% | -64.57% | -65.64% | -60.12% | -56.29% | -63.56% | -70.80% |